Literature DB >> 24036214

SOX2 plays a critical role in EGFR-mediated self-renewal of human prostate cancer stem-like cells.

Adrian P Rybak1, Damu Tang.   

Abstract

SOX2 is an essential transcription factor for stem cells and plays a role in tumorigenesis, however its role in prostate cancer stem cells (PCSCs) remains unclear. We report here a significant upregulation of SOX2 at both mRNA and protein levels in DU145 PCSCs propagated as suspension spheres in vitro. The expression of SOX2 in DU145 PCSCs is positively regulated by epidermal growth factor receptor (EGFR) signaling. Activation of EGFR signaling, following the addition of epidermal growth factor (EGF) or ectopic expression of a constitutively-active EGFR mutant (EGFRvIII), increased SOX2 expression and the self-renewal of DU145 PCSCs. Conversely, a small molecule EGFR inhibitor (AG1478) blocked EGFR activation, reduced SOX2 expression and inhibited PCSC self-renewal activity, implicating SOX2 in mediating EGFR-dependent self-renewal of PCSCs. In line with this notion, ectopic SOX2 expression enhanced EGF-induced self-renewal of DU145 PCSCs, while SOX2 knockdown reduced PCSC self-renewal with EGF treatment no longer capable of enhancing their propagation. Furthermore, SOX2 knockdown reduced the capacity of DU145 PCSCs to grow under anchorage-independent conditions. Finally, DU145 PCSCs generated xenograft tumors more aggressively with elevated levels of SOX2 expression compared to xenograft tumors derived from non-PCSCs. Collectively, we provide evidence that SOX2 plays a critical role in EGFR-mediated self-renewal of DU145 PCSCs.
© 2013.

Entities:  

Keywords:  EGFR; Prostate cancer stem cell; SOX2; Self-renewal

Mesh:

Substances:

Year:  2013        PMID: 24036214     DOI: 10.1016/j.cellsig.2013.08.041

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  44 in total

1.  Understanding the mechanism underlying the acquisition of radioresistance in human prostate cancer cells.

Authors:  Kosho Murata; Ryo Saga; Satoru Monzen; Echi Tsuruga; Kazuki Hasegawa; Yoichiro Hosokawa
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

Review 2.  Common stemness regulators of embryonic and cancer stem cells.

Authors:  Christiana Hadjimichael; Konstantina Chanoumidou; Natalia Papadopoulou; Panagiota Arampatzi; Joseph Papamatheakis; Androniki Kretsovali
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

Review 3.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

4.  IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG.

Authors:  S Samanta; H Sun; H L Goel; B Pursell; C Chang; A Khan; D L Greiner; S Cao; E Lim; L D Shultz; A M Mercurio
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

5.  The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.

Authors:  Michelle Shen; Shiqin Liu; Tanya Stoyanova
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

Review 6.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

Review 7.  Metformin and prostate cancer stem cells: a novel therapeutic target.

Authors:  M J Mayer; L H Klotz; V Venkateswaran
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-07-28       Impact factor: 5.554

Review 8.  Paradoxical role of SOX2 in gastric cancer.

Authors:  Estefania Carrasco-Garcia; Juliana C Santos; Idoia Garcia; Mitsue Brianti; Mikel García-Puga; José Pedrazzoli; Ander Matheu; Marcelo L Ribeiro
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

9.  Roles of sex-determining region Y-box 2 in cell pluripotency and tumor-related signaling pathways.

Authors:  Jingjie Wang; Huijuan Zeng; Hanjun Li; Juanjuan Zhang; Shaohua Wang
Journal:  Mol Clin Oncol       Date:  2015-09-08

10.  PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III.

Authors:  Jeong-Yub Kim; Hee-Jin Kim; Chan-Woong Jung; Byung-Il Choi; Dae-Hee Lee; Myung-Jin Park
Journal:  Oncogene       Date:  2020-11-13       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.